Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriPath expands VIAS menu

This article was originally published in The Gray Sheet

Executive Summary

VIAS (Ventana Image Analysis System) can now be used to measure levels of tumor suppressor biomarker p53 in breast biopsy samples, with 510(k) clearance announced Oct. 12. High expression of the p53 protein has been linked to more aggressive breast cancers, and precise quantification can aid pathologists in forming a diagnosis and planning the appropriate course of treatment, TriPath Imaging says. The VIAS system, distributed by Ventana Medical Systems, also is cleared for estrogen and progesterone receptor applications, as well as Ki-67 and HER-2/neu assays (1"The Gray Sheet" June 13, 2005, p. 24)...

You may also be interested in...



TriPath Diagnostic Products Launched In May Lead To Stock Gain

TriPath Imaging's launch of two diagnostic products in May helped drive a 33.8% increase in the firm's stock price to $8.59

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

MT024098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel